Product Details

Product name: GW501516 (cardarine)
Alias: GSK-516
CAS: 317318-70-0
M.F.: C21H18F3NO3S2
M.W.: 453.5
M.P.: 134-136°C
Appearance: white solid
Usage: It had been investigated as a potential treatment for obesity, diabetes, dyslipidemia and cardiovascular disease. GW501516 could be used by athletes as an ergogenic performance enhancing drug.
GW-501516
GW-501516 is a unique medication officially classified as a PPAR receptor agonist (PPAR-RA). Research for this medication began in 1992 in a conjoined effort between GlaxoSmithKline (GSK) and Ligand Pharmaceuticals. Research into this product was set forth in an effort to provide treatment for various cardiovascular diseases, as well as diabetes, obesity and other conditions. It was soon discovered that the PPAR-RA was highly effective at enhancing endurance, but it was also shown to carry a high potential cost. It was discovered that GW-501516 increased the chances of cancer significantly, and as a result, GSK dropped all further research. However, the studies that produced cancerous results used doses of GW-501516 that were 500 to even 1000 times the amount that a human being would take. If cancer is a risk with standard dosing is unknown.
GW-501516 Functions and Traits
GW-501516 binds to the PPAR receptor, specifically a group of nuclear receptors (sensors that detect thyroid and steroidal hormones in the body) that initiates the PGC-1a enzyme. This action leads to gene expression, specifically genes that revolve around energy expenditure.
Studies involving GW-501516 have shown to increase the metabolism of fatty acids in rats. It was also shown in the same studies to reduce the odds of obesity despite poor eating habits as well as prevent Type-2 diabetes. GW-501516 was also shown to increase HDL (good cholesterol) and decrease LDL (bad cholesterol) in a study using monkeys. The effects seemed to hold true with or without exercise.
Effects of GW-501516
The effects of GW-501516 are fairly significant and may be a welcomed addition to the stack for a performance athlete. Increased endurance may be the PPAR-RA's most incredible attribute. Those who use the medication will find they do not tire out as easily and can train harder and longer. The cardiovascular endurance that comes with GW-501516 is so strong it has been shown to do away with the cardio issues that surround the popular anabolic steroid Trenbolone. Many who use Trenbolone report breathing becomes a bit more difficult and that cardio becomes a more arduous task. GW-501516 seems to negate this negative effect when using Tren.
The effects of GW-501516 also help tremendously with fat loss. If nothing else, you're able to perform your cardio more intensely and longer. Further, it doesn't carry any catabolic effect that is associated with many thermogenics or fat burners, meaning muscle loss due to use is of no concern. More importantly, GW-501516 has been shown to increase nutrient efficiency. Simply put, you make better use of the nutrients you're consuming. Those who use the compound will find increased levels of glucose uptake and fat stores reduced.